glp-1 obesity drug news today september 2025 30 Alarming rise in weight loss GLP-1 overdoses Study predicts 16 new obesity

If managed well, GLP-1 therapies could become a cornerstone of Indias evolving approach to chronic disease management

Bagsvaerd, Denmark: Novo Nordisk

Ideally, the prescriber is someone you can work with long term, says John Morton, MD, MPH, chief of Bariatric and Minimally Invasive Surgery at Yale Medicine and a board-certified obesity medicine specialist

Tirzepatide: The Dual Agonist Tirzepatide is often referred to as the next generation GLP-1 because it targets two hormones : This dual mechanism seems to amplify its effects

Further, direct stimulation of the GLP-1 receptor on cholangiocytes can lead to enhanced cellular proliferation and an elevated likelihood of cholestasis [47]

Semaglutide and tirzepatide are associated with the highest rates of gastrointestinal symptoms, although these tend to attenuate over time and can be mitigated with gradual titration (Rosenstock et al., 2021)